These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
621 related articles for article (PubMed ID: 30400838)
1. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. Huang M; Huang B; Li G; Zeng S BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838 [TBL] [Abstract][Full Text] [Related]
2. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways]. Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051 [No Abstract] [Full Text] [Related]
3. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384 [TBL] [Abstract][Full Text] [Related]
4. Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis. Huang MP; Gu SZ; Huang B; Li GW; Xiong ZP; Tang T; Zeng SN Pharmacology; 2021; 106(9-10):509-519. PubMed ID: 34412054 [TBL] [Abstract][Full Text] [Related]
5. Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways. Song J; Guan Z; Song C; Li M; Gao Z; Zhao Y Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846786 [TBL] [Abstract][Full Text] [Related]
6. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873 [TBL] [Abstract][Full Text] [Related]
7. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31. Zhong N; Zhuang W; Huang Q; Wang Q; Jin W J Cell Mol Med; 2021 Nov; 25(21):10039-10048. PubMed ID: 34590406 [TBL] [Abstract][Full Text] [Related]
8. Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway. Xie K; Nian J; Zhu X; Geng X; Liu F Int J Clin Exp Pathol; 2015; 8(11):14028-33. PubMed ID: 26823715 [TBL] [Abstract][Full Text] [Related]
9. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. Gao Z; Shi M; Wang Y; Chen J; Ou Y Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851 [TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244 [TBL] [Abstract][Full Text] [Related]
11. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway. Zhu B; Wei Y Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323 [TBL] [Abstract][Full Text] [Related]
13. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434 [TBL] [Abstract][Full Text] [Related]
14. Total Flavones of Abelmoschus manihot Exhibits Pro-Angiogenic Activity by Activating the VEGF-A/VEGFR2-PI3K/Akt Signaling Axis. Zhu GS; Tang LY; Lv DL; Jiang M Am J Chin Med; 2018; 46(3):567-583. PubMed ID: 29595071 [TBL] [Abstract][Full Text] [Related]
15. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma. Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells. Liu ZJ; Zhou YJ; Ding RL; Xie F; Fu SZ; Wu JB; Yang LL; Wen QL PLoS One; 2018; 13(7):e0200845. PubMed ID: 30052652 [TBL] [Abstract][Full Text] [Related]
17. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. Lin Y; Zhai E; Liao B; Xu L; Zhang X; Peng S; He Y; Cai S; Zeng Z; Chen M Oncotarget; 2017 Feb; 8(7):11990-12002. PubMed ID: 28061477 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling. Jin J; Yuan F; Shen MQ; Feng YF; He QL Mol Cell Biochem; 2013 Sep; 381(1-2):267-72. PubMed ID: 23749166 [TBL] [Abstract][Full Text] [Related]
19. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327 [TBL] [Abstract][Full Text] [Related]
20. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]